Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2939615 | 0.91 | GAA (0.42) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18446 | 0.89 | ALDH1A1 (0.53) | GAAMGAMSIMGAM2ALDH1A1 | |
| Ether SCHEMBL28615296 | 0.82 | MGAM (0.36) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16811766 | 0.82 | ALDH1A1 (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2945975 | 0.81 | HCAR2 (0.38) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL25706 | 0.81 | ALDH1A1 (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL6824967 | 0.80 | ALDH1A1 (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1857628 | 0.80 | ALDH1A1 (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2948744 | 0.79 | ALDH1A1 (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7736670 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4347346-A | DIALKYLACETYLENEDICARBOXYITE TO PREVENT PREMATURE GELATION | GENERAL ELECTRIC COMPANY (US) | 1982-08-31 | — | — | US | claimed |
| US-11974991-B1 | Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates | King Faisal University (SA) | 2024-05-07 | — | — | US | disclosed |
| US-11530217-B1 | Antitubercular compounds | King Faisal University (SA) | 2022-12-20 | — | — | US | disclosed |
| WO-2017032780-A1 | COMPOSITION FOR FORMING TRANSPARENT CONDUCTIVE LAYER AND METHOD FOR PREPARING THE SAME | SOLVAY SA (BE) | 2017-03-02 | — | — | WO | disclosed |
| EP-3135736-A1 | COMPOSITION FOR FORMING TRANSPARENT CONDUCTIVE LAYER | Solvay SA (BE) | 2017-03-01 | — | — | EP | disclosed |
| CN-105793363-A | Conductive compositions and layers made therefrom | 索尔维公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2016097128-A1 | PROCESS FOR PRODUCING POLYVINYLMETALLOCENE, AND POLYVINYLMETALLOCENE COMPOUND OBTAINED THEREFROM | SOLVAY SA (BE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016071484-A1 | COMPOSITION FOR FORMING TRANSPARENT CONDUCTIVE LAYER AND METHOD FOR PREPARING THE SAME | SOLVAY SA (BE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015075181-A1 | CONDUCTIVE COMPOSITION AND LAYER MA DE THEREFROM | SOLVAY SA (BE) | 2015-05-28 | — | — | WO | disclosed |
| EP-2876141-A1 | Conductive polymer composition and layer made therefrom | Solvay SA (BE) | 2015-05-27 | — | — | EP | disclosed |
| US-20080038644-A1 | Nonaques Electrolyte Solution And Lithium Secondary Battery Using Same | UBE INDUSTRIES, LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| WO-2007146603-A2 | ADHESION PROMOTING ADDITIVE | AVERY DENNISON CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-1961452-A | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1758198-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-0391163-B1 | Adherent silicone coating | GEN ELECTRIC (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5082871-A | Acetylenedicarboxylate gelation inhibitor | GENERAL ELECTRIC COMPANY (US) | 1992-01-21 | — | — | US | disclosed |
| EP-0391163-A2 | Adherent silicone coating | GENERAL ELECTRIC COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
| US-4943601-A | Coating with improved adhesion | GENERAL ELECTRIC COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4347346-A | DIALKYLACETYLENEDICARBOXYITE TO PREVENT PREMATURE GELATION | GENERAL ELECTRIC COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
| US-4340710-A | ETHYLENICALLY UNSATURATED ISOCYANURATE AND DIALKYL ACETYLENEDICARBOXYLATE STABILIZERS TO INHIBIT PREMATURE GELATION | GENERAL ELECTRIC COMPANY (US) | 1982-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11974991-B1 | Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates | ADORA2A, ADORA1, ADORA3 | GAA 2856/4885MGAM 3821/4885SI 2645/4885 |
| US-11530217-B1 | Antitubercular compounds | MT-CO3, NOS3, MT-ND3 | GAA 4322/4885MGAM 3104/4885SI 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.